dc.contributor.author | Kharman-Biz, Amirhossein | |
dc.contributor.author | Gao, Hui | |
dc.contributor.author | Ghiasvand, Reza | |
dc.contributor.author | Zhao, Chunyan | |
dc.contributor.author | Zendehdel, Kazem | |
dc.contributor.author | Dahlman-Wright, Karin | |
dc.date.accessioned | 2015-10-20T10:56:57Z | |
dc.date.available | 2015-10-20T10:56:57Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | BMC Cancer. 2013 Sep 28;13(1):441 | |
dc.identifier.uri | http://hdl.handle.net/10852/47217 | |
dc.description.abstract | Background
The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer.
Methods
We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student’s t-test, one-way ANOVA, logistic regression and Pearson’s correlation coefficient for statistical analyses.
Results
We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01).
Conclusions
Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer. | |
dc.language.iso | eng | |
dc.rights | Kharman-Biz et al.; licensee BioMed Central Ltd. | |
dc.rights | Attribution 2.0 Generic | |
dc.rights.uri | http://creativecommons.org/licenses/by/2.0/ | |
dc.title | Expression of activator protein-1 (AP-1) family members in breast cancer | |
dc.type | Journal article | |
dc.date.updated | 2015-10-20T10:56:58Z | |
dc.creator.author | Kharman-Biz, Amirhossein | |
dc.creator.author | Gao, Hui | |
dc.creator.author | Ghiasvand, Reza | |
dc.creator.author | Zhao, Chunyan | |
dc.creator.author | Zendehdel, Kazem | |
dc.creator.author | Dahlman-Wright, Karin | |
dc.identifier.doi | http://dx.doi.org/10.1186/1471-2407-13-441 | |
dc.identifier.urn | URN:NBN:no-51340 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/47217/1/12885_2013_Article_4091.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 441 | |